Evaluation of the effect of squill oxymel In COPD

Evaluation the effect of squill oxymel, Traditional Medicine product, in the treatment of chronic obstructive pulmonary disease (COPD) in patients 18 to 60 years old: triple-blind randomized Clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040919912N2

Enrollment

Registered

2016-09-22

Start date

2016-10-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease (COPD). Chronic obstructive pulmonary disease, unspecified

Interventions

Intervention 1: Intervention Group (Medication): Squill Oxymel (traditional medicine products) Oral Syrup (250ml), 10 ml twice a day for 6 weeks. Intervention 2: Control Group (placebo): a mixture of

Treatment - Drugs

Intervention Group (Medication): Squill Oxymel (traditional medicine products) Oral Syrup (250ml), 10 ml twice a day for 6 weeks

Control Group (placebo): a mixture of honey, water, color additive, etc. Oral Syrup (250ml), 10 ml twice a day for 6 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18 to 60 years; patients with GOLD stage IIA COPD who have clinical criteria include: FEV1/FVC less than 0.7 of the predicted and FEV1 between 50% to 80% of the predicted; treated with conventional drugs; Lack of pregnancy; Lack of breastfeeding; Lack of the use other herbal medicines; Lack of active peptic ulcer and cardiovascular disease (especially heart block) or renal disease; Not concomitant use of anticoagulant; Non-smoking. Exclusion criteria: Add or remove the drugs that interferes with COPD (such as NSAIDs); Infections leading to hospitalization; the patient's unwillingness to continue treatment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Distance traveled in the 6MWT. Timepoint: Before and after the intervention (end of week 6). Method of measurement: 6-minute walk test (6MWT).	—

Secondary

Measure	Time frame
Quality of life. Timepoint: before and after the intervention (6 week). Method of measurement: quality of life questionnaires St. George (SGRQ).;Blood oxygen saturation (SaO2). Timepoint: before and after the intervention (6 week). Method of measurement: 6-minute walk test (6MWT).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Hossein Karegar-Borzi

Tehran University of Medical Sciences

h-karegar@razi.tums.ac.ir+98 21 2298 8550

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026